Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; effective date TBD

Ernexa Therapeutics Inc.

Dr. Kevin D'Amour, Chief Scientific Officer, submitted resignation notice on July 21, 2022.
Effective date of resignation not yet determined by the Company and Dr. D'Amour.
No successor or interim CSO announced in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Kevin D'Amour

Chief Scientific Officer

ERNA · Ernexa Therapeutics Inc.

Filed: July 27, 2022, 7:59 PM ET

On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-027135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.